Cell Foundry with High Product Specificity and Catalytic Activity for 21-Deoxycortisol Biotransformation

Shuting Xiong,Ying Wang,Mingdong Yao,Hong Liu,Xiao Zhou,Wenhai Xiao,Yingjin Yuan
DOI: https://doi.org/10.1186/s12934-017-0720-y
IF: 6.352
2017-01-01
Microbial Cell Factories
Abstract:21-deoxycortisol (21-DF) is the key intermediate to manufacture pharmaceutical glucocorticoids. Recently, a Japan patent has realized 21-DF production via biotransformation of 17-hydroxyprogesterone (17-OHP) by purified steroid 11β-hydroxylase CYP11B1. Due to the less costs on enzyme isolation, purification and stabilization as well as cofactors supply, whole-cell should be preferentially employed as the biocatalyst over purified enzymes. No reports as so far have demonstrated a whole-cell system to produce 21-DF. Therefore, this study aimed to establish a whole-cell biocatalyst to achieve 21-DF transformation with high catalytic activity and product specificity.
What problem does this paper attempt to address?